Markets:

Overview

News

Currencies

International

Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

9.930 UNCHANGED

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy ↗

October 31, 2022

Via Benzinga

U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

October 28, 2022

From Amicus Therapeutics, Inc.

Via GlobeNewswire

Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

October 27, 2022

From Amicus Therapeutics, Inc.

Via GlobeNewswire

Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease ↗

March 16, 2022

Amicus Therapeutics Inc (NASDAQ: FOLD) has

Via Benzinga

Amicus Therapeutics Announces Participation at World Muscle Society 2022

October 11, 2022

From Amicus Therapeutics, Inc.

Via GlobeNewswire

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗

August 08, 2022

U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday ↗

August 08, 2022

Gainers

Via Benzinga

This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.

Via Benzinga

PayPal, SoFi Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

August 03, 2022

PayPal Holdings, Inc. (NASDAQ: PYPL) rose 12% to $100.35 in pre-market trading after the company reported better-than-expected Q2 results and raised FY22 EPS guidance.

Via Benzinga

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

Short Volatility Alert: Amicus Therapeutics, Inc. ↗

June 22, 2022

On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Biotech Stocks With Key Catalysts for May ↗

May 11, 2022

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.

Via InvestorPlace

FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months ↗

May 10, 2022

The U.S.

Via Benzinga

Recap: Amicus Therapeutics Q1 Earnings ↗

May 09, 2022

Amicus Therapeutics (NASDAQ:FOLD) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Amicus Therapeutics ↗

May 06, 2022

Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Amicus...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2022

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...

Via Benzinga

Amicus Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 27, 2022

Amicus Therapeutics (NASDAQ:FOLD) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall ↗

February 24, 2022

Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Amicus Therapeutics Earnings Preview ↗

February 23, 2022

Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022 ↗

January 14, 2022

Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

January 14, 2022

Keybanc cut Robinhood Markets, Inc. (NASDAQ:HOOD...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher ↗

January 10, 2022

Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29. The U.S....

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.